The ORR of patients treated with Osimertinib was 73.2% (584/798), whereas the ORR of those treated with EGFR-TKIs/chemotherapy regimens was 53.6% (339/633); further analysis indicated that Osimertinib therapy could improve ORR for advanced NSCLC patients with EGFR mutations compared with EGFR-TKIs/chemotherapy (OR = 1.76; 95% CI = 1.14–2.72; P = .011) (Fig. 4A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.